TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06657144: A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Sponsor: Coherus Oncology, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 154 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,419,032

Rescue Site Savings

+$1,602,216

Unlock Full NCT06657144 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06657144 Rescue Dossier →